Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891904 · ClinicalTrials.gov registry record · NA
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
A NA study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT00891904 is a NA study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT00891904, a NA study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving stereotactic body radiation therapy together with cetuximab may kill more tumor cells. PURPOSE: This clinical trial is studying the side effects of radiation therapy given together with cetuximab and to see how well it works in treating patients with recurrent head and neck cancer.
Interventions
- RADIATION stereotactic body radiation therapy
- BIOLOGICAL cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00891904
The ClinicalTrials.gov registry entry for NCT00891904 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which stereotactic body radiation therapy is the first listed.
NCT00891904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00891904 about?
NCT00891904 is a clinical study titled "Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer". RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cell...
What is the current status of trial NCT00891904?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2009-04.
What interventions are being tested in trial NCT00891904?
The interventions under investigation include: stereotactic body radiation therapy (RADIATION), cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00891904?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.